Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$83.30−4.45 (-5.07%)
Close on Nov 13, 2026Market cap $1.23BP/E –Yield –
Inhibrx Biosciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Inhibrx Biosciences's enterprise value was $1.38B on Nov 11, 2026, against $1.17B a year earlier. Over the last 5 years it ranged from -$91.77M to $1.91B, with a median of $98.22M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.38B | +25.9% |
| 2025 | Dec 31, 2025 | $1.09B | +4006.4% |
| 2024 | Dec 31, 2024 | $26.60M | -76.2% |
| 2023 | Dec 29, 2023 | $111.93M | +18.2% |
| 2022 | Dec 30, 2022 | $94.70M | -68.6% |
| 2021 | Dec 31, 2021 | $301.43M | +62.9% |
| 2020 | Dec 31, 2020 | $185.03M | – |
See a number that looks wrong?